Sagar Vaidya
Director

Dr. Sagar A. Vaidya M.D. Ph.D. is a drug developer and biotech executive with over 20 years of experience across academia, biotech, and the pharmaceutical industry. Dr. Vaidya currently serves as Chief Medical Officer at Cerevance, a privately held biotechnology company focused on novel treatments for neurodegenerative diseases. Prior to Cerevance, Dr. Vaidya was the Vice President of Clinical Development at Travere Therapeutics where he led clinical development for the company’s metabolic and neurology pipeline, including an investigational therapy for HCU. Previously, Dr. Vaidya served in leadership roles in clinical development at Sangamo Therapeutics and BioMarin Pharmaceuticals. Dr. Vaidya completed his Infectious Diseases fellowship at Massachusetts General Hospital, Internal Medicine/Pediatrics residency at Icahn School of Medicine at Mount Sinai Hospital, and received his M.D./Ph.D. degrees from David Geffen School of Medicine at UCLA. Dr. Vaidya remains committed to finding new treatments for rare diseases and is proud to serve on the Board at HCUNA.